CompoAtlas

e'lifexir® ESENCIALL® VENTRE PLAT FENOUIL

Food supplement declared in France, decision dated 2 May 2025

e'lifexir® ESENCIALL® VENTRE PLAT FENOUIL, from LABORATORIOS PHERGAL S.A., is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: fructo-oligosaccharides 2,400 mg per day, Foeniculum vulgare 300 mg per day. 1 rule of use applies to its ingredients (limits and warnings).

Brand
e'lifexir® ESENCIALL®
Food business operator placing the product on the market
LABORATORIOS PHERGAL S.A.
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Autre : Comprimé à mâcher
Daily dose
2 a 4 comprimés par jour
Directions for use
Prendre 2 a 4 comprimés par jour, après les repas, en les dissolvant lentement dans la bouche
Intended populations
General population
Not recommended (according to the manufacturer)
Breastfeeding women, Children (under 12), Pregnant women
Objectives stated by the manufacturer (these are not authorised claims)
Digestion

Declaration 261125, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Foeniculum vulgare Mill.Parties aériennesExtrait sec aqueux300 mg

Substances

NamePer day
fructo-oligosaccharides2,400 mg

Additives

E420, E470b, E967

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

• Ne pas dépasser la dose journalière recommandée. • Une consommation excessive peut avoir des effets laxatifs ou provoquerun inconfort intestinal. • Ne pas prendre en même temps que des médicaments ou d'autres compléments alimentaires à base de fibres. • Déconseillé en cas de d'allergie croisée connue, en particulier à la famille des Apiaceae (anis, céleri, etc) ou au pollen d’armoise ou à l’anéthole. • Conserver hors de la portée des jeunes enfants. • Déconseillé aux enfants de moins de 12 ans, femmes enceintes ou allaitantes. • Conserver dans un endroit frais et sec. • Ne pas utiliser comme substitut d'une alimentation équilibrée. • Il est important de suivre une alimentation variée et équilibrée et un mode de vie sain.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Foeniculum vulgare Mill.
    Read the warning, when it applies and the studies cited

    BITTER FENNEL- FOENICULUM VULGARE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024, 2007).

    Sources cited by Health Canada (2)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Condition of application: Essential oil and Tincture.

    Ask a health care practitioner before use if you are taking any medications including birth control pills or hormone therapy or other health products (EMA 2007).

    Sources cited by Health Canada (1)
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (EMA 2024, 2007).

    Sources cited by Health Canada (2)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Health Canada monograph dated 29 November 2024

    SWEET FENNEL -FOENICULUM VULGARE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024).

    Sources cited by Health Canada (1)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (EMA 2024).

    Sources cited by Health Canada (1)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf

    Health Canada monograph dated 29 November 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : e'lifexir® ESENCIALL®

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “e'lifexir® ESENCIALL® VENTRE PLAT FENOUIL: composition and regulation”, https://compoatlas.com/en/supplements/products/261125-e-lifexir-esenciall-ventre-plat-fenouil, updated 15 November 2026.

Enter to analyse, Shift+Enter for a new line